PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer.
Saved in:
| Title: | PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer. |
|---|---|
| Authors: | Gordon N; Department of Cancer Biology, Jefferson University, Philadelphia, PA, USA., Gallagher PT; Department of Cancer Biology, Jefferson University, Philadelphia, PA, USA., Richter OI; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA., Poudel Neupane N; Department of Cancer Biology, Jefferson University, Philadelphia, PA, USA., Mandigo AC; Department of Cancer Biology, Jefferson University, Philadelphia, PA, USA., McCann JJ; Department of Cancer Biology, Jefferson University, Philadelphia, PA, USA., Dylgjeri E; Department of Cancer Biology, Jefferson University, Philadelphia, PA, USA., Vasilevskaya I; Department of Cancer Biology, Jefferson University, Philadelphia, PA, USA., McNair C; Department of Cancer Biology, Jefferson University, Philadelphia, PA, USA., Paller CJ; Department of Oncology, Johns Hopkins University, Baltimore, MD, USA., Kelly WK; Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA., Knudsen KE; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.; The American Cancer Society, Philadelphia, PA, USA., Schiewer MJ; Department of Cancer Biology, Jefferson University, Philadelphia, PA, USA.; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.; Department of Urology, Thomas Jefferson University, Philadelphia, PA, USA.; Department of Pharmacology/Physiology/Cancer Biology, Thomas Jefferson University, Philadelphia, PA, USA., Shafi AA; Department of Cancer Biology, Jefferson University, Philadelphia, PA, USA.; Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.; The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA. |
| Source: | Molecular oncology [Mol Oncol] 2026 Jun; Vol. 20 (6), pp. 1626-1642. Date of Electronic Publication: 2026 Jan 14. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1878-0261 |
|---|---|
| DOI: | 10.1002/1878-0261.70183 |
